CLI Specimen Analyser for Ex-vivo Assessment of Margin and Lymph Node Status in Breast Cancer Surgical Specimens

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2015 by Lightpoint Medical Limited
Guy's and St Thomas' NHS Foundation Trust
King's College London
Information provided by (Responsible Party):
Lightpoint Medical Limited Identifier:
First received: January 14, 2014
Last updated: July 16, 2015
Last verified: July 2015

This study will assess the feasibility of a Cerenkov Luminescence Imaging (CLI) Specimen Analyser for intra-operative analysis of wide local excision (WLE) specimens and lymph nodes.

Breast Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Pilot Study to Evaluate Cerenkov Luminescence Imaging for Measuring Margin and Lymph Node Status in Breast Cancer Surgical Specimens

Resource links provided by NLM:

Further study details as provided by Lightpoint Medical Limited:

Primary Outcome Measures:
  • Tumour margin status of the Wide Local Excision specimen as determined by CLI [ Time Frame: Intra-operative ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Metastatic status of dissected lymph nodes as determined by CLI [ Time Frame: Intra-operative ] [ Designated as safety issue: No ]
  • Radiation dosimetry to operating theatre, recovery area and pathology staff [ Time Frame: Up to 24 hours after injection of radiopharmaceutical ] [ Designated as safety issue: Yes ]
  • Ease of use of CLI Specimen Analyser [ Time Frame: Intra-operative ] [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: June 2014
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
All participants
Females with a diagnosis of breast cancer scheduled to have breast conserving surgery +/- sentinel lymph node biopsy or axillary lymph node dissection

Detailed Description:

Subject's blood glucose level will be measured on the day of surgery. Subjects with a blood glucose level < 12 mmol/l receive an intravenous injection of 5 MBq/kg, up to a maximum 300 MBq of 18F-fluorodeoxyglucose (18F-FDG) prior to surgery. Breast cancer surgery will be performed per standard of care. SLNB will be performed using a dose of 150 MBq technetium 99 (99mTc) nanocolloid and patent blue dye. The resected WLE specimen and lymph nodes will be imaged in the CLI specimen analyser. A member of the research team who is not the operating surgeon will capture CLI images intra-operatively.

Prior to CLI, the WLE specimen will be placed in a specimen holder. CLI is performed according to the CLI specimen analyser instructions for use. All CLI will be performed between 1 and 3 hours post injection of 18F-FDG.

The WLE specimen will then undergo standard of care histopathological analysis with a positive margin defined as either invasive carcinoma or ductal carcinoma in situ (DCIS) within 2mm of the specimen surface. Lymph nodes will also be examined according to standard of care histopathological analysis.

The CLI results will not be used to influence any surgical or clinical decision-making.

All staff in the operating theatre and the recovery area caring for the patient, and pathology staff processing surgical specimens will wear badge dosimeters. Staff handling surgical specimens will also wear ring dosimeters.


Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Female patients ≥30 years of age with known breast cancer scheduled for breast-conserving surgery (BCS) +/- sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND)


Inclusion Criteria

  • Females ≥30 years of age with a diagnosis of invasive breast cancer or DCIS
  • Scheduled for BCS +/- SLNB or ALND
  • Females of childbearing age must have a negative pregnancy test (by Beta HCG qualitative analysis), must have had a history of a surgical sterilisation, or must give history of no menses in past twelve months

Exclusion Criteria

  • Surgery or radiotherapy in the operated breast in the past 2 years
  • Neoadjuvant systemic therapy
  • Patients not suitable for BCS
  • Blood glucose level ≥ 12 mmol/l on the day of surgery
  • Known hypersensitivity to 18F-FDG
  • Any patient who is pregnant or lactating
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02037269

Contact: Anand D Purushotham, MBBS FRCS MD

United Kingdom
Guy's Hospital Recruiting
London, United Kingdom, SE1 9RT
Contact: Sweta Sethi    0044 (0)20 7188 0743   
Contact: Maarten Grootendorst    0044 (0)20 7188 0743   
Principal Investigator: Anand D Purushotham, MBBS FRCS MD         
Sponsors and Collaborators
Lightpoint Medical Limited
Guy's and St Thomas' NHS Foundation Trust
King's College London
Principal Investigator: Anand D Purushotham, MBBS FRCS MD King's College London
  More Information

Additional Information:
No publications provided

Responsible Party: Lightpoint Medical Limited Identifier: NCT02037269     History of Changes
Other Study ID Numbers: LPM-001
Study First Received: January 14, 2014
Last Updated: July 16, 2015
Health Authority: United Kingdom: Research Ethics Committee
United Kingdom: National Health Service

Keywords provided by Lightpoint Medical Limited:
Cerenkov Luminescence Imaging, CLI, Margin Status

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases processed this record on July 27, 2015